BiomX Overview
BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria in the treatment of chronic diseases, such as cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis, and colorectal cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. The company's platforms use computational and synthetic biology and research from Doctors Rotem Sorek, Eran Elinav, and Eran Segal of the Weizmann Institute of Science and Doctor Timothy K. Lu of the Massachusetts Institute of Technology.
Cumulative Funding Raised Over Time ($)
—Dec 2015
$32.0MFeb 2019
$39.5MFeb 2023
$51.5MFeb 2025
$54.5MJan 2022
$104.5MMar 2024
$128.5MMay 2017
$128.5MOct 2019
Latest News
growth-positive
BiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development Pathways
BiomX Inc, a clinical-stage company, provided an update on its BX004 Phase 2b trial for cystic fibrosis, which is currently under a clinical hold by the FDA in the U.S. The company has addressed the FDAs queries regarding the third-party nebulizer used in the trial and received new feedback outlining potential development strategies. Despite the U.S. hold, European enrollment and dosing continue to progress well, with topline results expected in early 2026. BiomX is optimistic about resolving the FDAs concerns and lifting the clinical hold soon.
Product StageFDA approved/pending approval
growth-positive
BiomX CEO to Present at H.C. Wainwright 27th Annual Global Investment Conference
BiomX Inc, a clinical-stage company, announced positive topline results from its Phase 2 trial of BX211, a phage therapy for treating Diabetic Foot Osteomyelitis (DFO). The results showed significant reductions in ulcer size and depth, indicating the treatments efficacy. The company plans to present these findings at the H.C. Wainwright 27th Annual Global Investment Conference. BiomX is preparing for a registrational trial, pending FDA discussions. BX211 targets S. aureus, a common cause of DFO, and has shown promise in reducing infection-related complications. The company continues to advance its phage therapy platform to address unmet medical needs.
Product StageFDA approved/pending approval
growth-negative
BiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis
BiomX Inc, a clinical-stage company, announced that the U.S. FDA has placed a clinical hold on its Phase 2b trial of BX004, a phage therapy for cystic fibrosis. The hold is due to concerns about a third-party nebulizer device used in the trial, not the BX004 drug itself. BiomX has submitted additional data to address the FDAs concerns and expects the hold to be temporary. Enrollment and dosing continue outside the U.S. The company remains optimistic about resolving the issue promptly and is committed to transparency with stakeholders.
Product Stage
growth-positive
BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates
BiomX Inc, a clinical-stage company, announced positive Phase 2 results for its phage therapy BX211, which showed over 40% reduction in ulcer size in diabetic foot osteomyelitis patients. Additionally, new data for BX004 demonstrated significant bacterial reduction. The company is planning a potential registrational study for BX211 and has commenced a Phase 2b trial for BX004 in Cystic Fibrosis. FDA feedback on their real-world evidence strategy is expected in the second half of 2025. These developments position BiomX for multiple value-driving catalysts over the next year.
Product StageFDA approved/pending approval
growth-positive
BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025
BiomX Inc., a clinical-stage company specializing in phage therapies, announced it will release its second quarter 2025 financial results and program updates on August 13, 2025. The company will host a conference call and webcast to discuss these updates. BiomX focuses on developing phage cocktails and personalized treatments targeting harmful bacteria for chronic diseases. The announcement indicates the companys ongoing progress in its clinical trials and its commitment to transparency with investors. The event is expected to provide insights into the companys financial health and future plans.
Product Stage
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $143.5M |
| Last funding | $12M |
| Stage | Public |
| Rounds | 10 |
| Investors | 15 |
Team Members
7
Employees: 51-200
Web & Social Links
| Website | www.biomx.com |
| Careers | Careers page |
Locations
Einstein St 22, Ness Ziona, Israel
Photos & Videos
No files yet
BiomX Business
Business models
B2B
Product stage
Clinical Trial
Employees
51-200
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesLife SciencesCosmeticsPharmaceuticalsHealthcarePatientsCore Technology
Artificial IntelligenceBiologicalsMicroorganismsTags (15)
bioconvergencediabetesinflammatory-diseasescancertargeted-therapymicrobiologypharmaceuticalsmicrobiomebacteriaartificial-intelligencedrug-discoverygenomicsmachine-learningbiomarkersautoimmune-diseasesBiomX Financials
$143.5M
Total funding
Undisclosed
Capital raised
$12M
Last funding
Public
Funding stage
10
Total rounds
15
Investors
Cumulative Funding Raised Over Time ($)
—Dec 2015
$32.0MFeb 2019
$39.5MFeb 2023
$51.5MFeb 2025
$54.5MJan 2022
$104.5MMar 2024
$128.5MMay 2017
$128.5MOct 2019
Private Equity Funding
PIPE
Feb 2025
$12M
Deerfield Management (Lead)
,
Cystic Fibrosis Foundation
PIPE
Mar 2024
$50M
OrbiMed, Cystic Fibrosis Foundation, Deerfield Management
PIPE
Feb 2023
$7.5M
Cystic Fibrosis Foundation, OrbiMed
PIPE
Jan 2022
$3M
Cystic Fibrosis Foundation
C Round
Oct 2019
Undisclosed
B Round
Feb 2019
$32M
OrbiMed, Seventure Partners, Mirae Asset, 8VC, RMGP Biopharma Investment Fund, Johnson & Johnson Innovation, SBI JI Innovation Fund, Handok, Takeda Ventures, KB Investment, Chong Kun Dang Pharma
A Round
May 2017
$24M
Takeda Ventures, OrbiMed, Johnson & Johnson Innovation
Seed
Dec 2015
Undisclosed
FutuRx
Non-Equity Funding
GrantEvent
Dec 2017
Undisclosed
Public Offering / Exit
POEvent
Jul 2021
Undisclosed
ReverseMergerEvent
Nov 2019
Undisclosed
Mergers & Acquisitions
MNAEvent
Mar 2024
Undisclosed
MNAEvent
Dec 2017
Undisclosed
BiomX Lifecycle
Cumulative Funding Raised Over Time
—Dec 2015
$32.0MFeb 2019
$39.5MFeb 2023
$51.5MFeb 2025
$54.5MJan 2022
$104.5MMar 2024
$128.5MMay 2017
$128.5MOct 2019
All Events
PIPE
Feb 2025
$12M
Deerfield Management (Lead)
,
Cystic Fibrosis Foundation
PIPE
Mar 2024
$50M
OrbiMed, Cystic Fibrosis Foundation, Deerfield Management
PIPE
Feb 2023
$7.5M
Cystic Fibrosis Foundation, OrbiMed
PIPE
Jan 2022
$3M
Cystic Fibrosis Foundation
C Round
Oct 2019
Undisclosed
B Round
Feb 2019
$32M
OrbiMed, Seventure Partners, Mirae Asset, 8VC, RMGP Biopharma Investment Fund, Johnson & Johnson Innovation, SBI JI Innovation Fund, Handok, Takeda Ventures, KB Investment, Chong Kun Dang Pharma
A Round
May 2017
$24M
Takeda Ventures, OrbiMed, Johnson & Johnson Innovation
Seed
Dec 2015
Undisclosed
FutuRx
GrantEvent
Dec 2017
Undisclosed
POEvent
Jul 2021
Undisclosed
ReverseMergerEvent
Nov 2019
Undisclosed
MNAEvent
Mar 2024
Undisclosed
MNAEvent
Dec 2017
Undisclosed
BiomX News
111 articles
growth-positive
BiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development Pathways
BiomX Inc, a clinical-stage company, provided an update on its BX004 Phase 2b trial for cystic fibrosis, which is currently under a clinical hold by the FDA in the U.S. The company has addressed the FDAs queries regarding the third-party nebulizer used in the trial and received new feedback outlining potential development strategies. Despite the U.S. hold, European enrollment and dosing continue to progress well, with topline results expected in early 2026. BiomX is optimistic about resolving the FDAs concerns and lifting the clinical hold soon.
Product StageFDA approved/pending approval
growth-positive
BiomX CEO to Present at H.C. Wainwright 27th Annual Global Investment Conference
BiomX Inc, a clinical-stage company, announced positive topline results from its Phase 2 trial of BX211, a phage therapy for treating Diabetic Foot Osteomyelitis (DFO). The results showed significant reductions in ulcer size and depth, indicating the treatments efficacy. The company plans to present these findings at the H.C. Wainwright 27th Annual Global Investment Conference. BiomX is preparing for a registrational trial, pending FDA discussions. BX211 targets S. aureus, a common cause of DFO, and has shown promise in reducing infection-related complications. The company continues to advance its phage therapy platform to address unmet medical needs.
Product StageFDA approved/pending approval
growth-negative
BiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis
BiomX Inc, a clinical-stage company, announced that the U.S. FDA has placed a clinical hold on its Phase 2b trial of BX004, a phage therapy for cystic fibrosis. The hold is due to concerns about a third-party nebulizer device used in the trial, not the BX004 drug itself. BiomX has submitted additional data to address the FDAs concerns and expects the hold to be temporary. Enrollment and dosing continue outside the U.S. The company remains optimistic about resolving the issue promptly and is committed to transparency with stakeholders.
Product Stage
growth-positive
BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates
BiomX Inc, a clinical-stage company, announced positive Phase 2 results for its phage therapy BX211, which showed over 40% reduction in ulcer size in diabetic foot osteomyelitis patients. Additionally, new data for BX004 demonstrated significant bacterial reduction. The company is planning a potential registrational study for BX211 and has commenced a Phase 2b trial for BX004 in Cystic Fibrosis. FDA feedback on their real-world evidence strategy is expected in the second half of 2025. These developments position BiomX for multiple value-driving catalysts over the next year.
Product StageFDA approved/pending approval
growth-positive
BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025
BiomX Inc., a clinical-stage company specializing in phage therapies, announced it will release its second quarter 2025 financial results and program updates on August 13, 2025. The company will host a conference call and webcast to discuss these updates. BiomX focuses on developing phage cocktails and personalized treatments targeting harmful bacteria for chronic diseases. The announcement indicates the companys ongoing progress in its clinical trials and its commitment to transparency with investors. The event is expected to provide insights into the companys financial health and future plans.
Product Stage
growth-positive
BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis
BiomX Inc, a clinical-stage company, has initiated patient dosing in its Phase 2b trial for BX004, a phage therapy targeting chronic pulmonary infections in cystic fibrosis patients caused by Pseudomonas aeruginosa. This marks a significant milestone in their development program, with topline results expected in Q1 2026. Previous Phase 1b/2a trials showed promising results, with 14.3% of patients achieving complete bacterial clearance after 10 days. The company anticipates FDA feedback in H2 2025, which could streamline the approval pathway. BiomX has secured Fast Track and Orphan Drug designations, positioning it well for further development of its phage-based therapy.
Product StageFDA approved/pending approval
growth-positive
BiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic Fibrosis
BiomX Inc, a clinical-stage company, has published a peer-reviewed article in Nature Communications validating its phage therapy platform. The article highlights results from a Phase 1b/2a trial for antibiotic-resistant P. aeruginosa infections, showing a significant bacterial reduction with no emergent resistance. The company is advancing to a Phase 2b trial of BX004, with results expected in Q1 2026. The study underscores the efficacy of BiomXs bacteriophage therapies in treating chronic cystic fibrosis infections, addressing limitations of traditional antibiotics. The publication provides third-party validation and strengthens BiomXs innovative approach to bacteriophage therapy.
Product Stage
growth-positive
BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference
BiomX Inc., a clinical-stage company, announced positive topline results from its Phase 2 trial of BX211 for treating Diabetic Foot Osteomyelitis (DFO). The results demonstrated that BX211 was safe, well-tolerated, and significantly reduced ulcer size and depth compared to placebo. These findings will be presented at the Biomed Israel 2025 conference. The company is planning a Phase 2/3 trial, pending FDA discussions. BiomXs phage therapies target antibiotic-resistant infections, aiming to reduce morbidity and mortality in chronic diseases.
Product Stage
growth-positive
BiomX Inc (PHGE) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience
BiomX Inc announced positive results from their Phase 2 trial of BX211 for diabetic foot osteomyelitis, showing significant improvements in ulcer size and depth. The company secured $12 million in financing, extending their financial runway into Q1 2026. Additionally, the U.S. Defense Health Agency provided $40 million in non-dilutive funding for BX211 development. Despite a reduced net loss in Q1 2025, the company faces financial challenges and is planning regulatory interactions for potential Phase 2/3 trials. There is strong interest from key opinion leaders and potential partners, indicating a promising path for regulatory approval and market entry.
Product StageInvestment
growth-positive
BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates
BiomX, a clinical-stage company, announced positive results from its Phase 2 trial of BX211 for treating diabetic foot osteomyelitis. The trial showed significant improvements in ulcer size and depth, marking a milestone in bacteriophage therapy. The company received approximately $40 million in non-dilutive funding from the U.S. Defense Health Agency and the Department of Navy. Additionally, BiomX secured $12 million in financing in February 2025, which will support the BX004 Phase 2b study in cystic fibrosis, expected to report results in Q1 2026. The company plans to advance BX211 to a Phase 2/3 trial, pending FDA feedback.
Product StageInvestment
growth-positive
BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025
BiomX Inc., a clinical-stage company specializing in phage therapies, announced a conference call and webcast scheduled for May 15, 2025, to discuss its first-quarter financial results and provide updates on its business and programs. The company focuses on developing phage cocktails and personalized treatments targeting harmful bacteria for chronic diseases. BiomX utilizes its BOLT platform to customize phage compositions against proprietary bacterial targets. The announcement is seen as growth-positive, highlighting the companys ongoing clinical trials and advancements in phage therapy.
Product Stage
growth-positive
BiomX (PHGE) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Shares of BiomX Inc. (PHGE) have been underperforming recently, losing 7.9% over the past two weeks. However, a hammer chart pattern has emerged, suggesting potential support and a possible trend reversal. This technical indicator, combined with rising optimism among Wall Street analysts regarding the companys future earnings, indicates a positive outlook. The consensus EPS estimate for the current year has increased by 34.9% over the last 30 days, signaling that analysts expect better-than-anticipated earnings. The hammer pattern, a popular candlestick charting technique, suggests that bears may be losing control, and a trend reversal could be on the horizon.
growth-negative
BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure
BiomX Inc., a clinical-stage company specializing in phage therapies, announced a going concern qualification in its audit opinion for the fiscal year ended December 31, 2024. This disclosure, made in compliance with NYSE American Company Guide requirements, indicates financial uncertainty about the companys ability to continue operations. BiomX focuses on developing phage cocktails and personalized treatments targeting harmful bacteria for chronic diseases. The company uses its BOLT platform to customize phage compositions. The announcement does not alter the companys 2024 audited financial statements or annual report. This financial warning could negatively impact the companys growth prospects.
growth-positive
BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)
BiomX announced positive results from its Phase 2 trial of BX211, a phage therapy for treating DFO associated with Staphylococcus aureus. The trial demonstrated that BX211 is safe, well-tolerated, and effective in reducing ulcer size and depth. The company plans to proceed with a Phase 2/3 trial, pending FDA feedback. BiomXs CEO highlighted the potential of phage therapy in addressing unmet needs in DFO treatment and its broader relevance in modern wound care. The company is supported by the U.S. Defense Health Agency and is committed to advancing phage therapy for chronic infections.
Product Stage
growth-positive
BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates
BiomX, a clinical-stage company, announced a series of financings totaling approximately $12 million to support the completion of the Phase 2b study of BX004, with results expected in Q1 2026. The company is also finalizing the analysis of topline results from the Phase 2 trial of BX211 for diabetic foot osteomyelitis (DFO), expected by March 2025. Additionally, BiomX is exploring real-world evidence in cystic fibrosis patients to assess the relationship between Pseudomonas aeruginosa reduction and clinical outcomes, ahead of regulatory discussions in the latter half of 2025. The company received a milestone payment from the U.S. Defense Health Agency, contributing to a total of $36.8 million in non-dilutive funding for the BX211 Phase 2 trial.
Investment
growth-positive
BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
BiomX Inc., a clinical-stage company, is set to announce its fourth quarter and full year 2024 financial results on March 25, 2025. The company specializes in developing phage therapies targeting specific pathogenic bacteria, with a focus on treating chronic diseases with unmet needs. BiomX is currently in the clinical trial phase, specifically Phase 2, for its treatment targeting diabetic foot osteomyelitis. The company uses its BOLT platform to customize phage compositions against proprietary bacterial targets. The upcoming financial results announcement is expected to include initial topline results from the ongoing trial, indicating potential growth and progress in their clinical endeavors.
Product Stage
growth-positive
BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million
BiomX Inc., a clinical-stage company, has secured approximately $12 million through a registered direct offering, concurrent private placement, and exercise of existing warrants. The financing will support the Phase 2b study of BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa. The studys topline results are expected in Q1 2026. The funding round was led by Deerfield Management Company, with participation from the Cystic Fibrosis Foundation and Nantahala Capital. BiomX plans to use the proceeds to advance its clinical programs and analyze real-world evidence. The FDA has granted BX004 Fast Track and Orphan Drug Designations.
InvestmentPIPE/PO
growth-positive
BiomX Inc. Receives Notice of Compliance with NYSE American Continued Listing Standards
BiomX Inc., a clinical-stage company specializing in phage therapies, announced that it has regained compliance with NYSE Americans continued listing standards. The company had previously faced listing deficiencies as of May 23, 2024, but has since resolved these issues, demonstrating compliance for two consecutive quarters. BiomX focuses on developing phage cocktails and personalized treatments targeting harmful bacteria for chronic diseases. The announcement includes forward-looking statements about the companys future compliance and performance, emphasizing the inherent uncertainties and risks involved. Investors are advised to review the risk factors detailed in BiomXs SEC filings.
growth-positive
BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates
BiomX Inc., a clinical-stage company, announced the completion of patient enrollment for its BX211 Phase 2 trial for diabetic foot osteomyelitis (DFO) and expects to report topline results in Q1 2025. The company also resolved manufacturing delays for its BX004 Phase 2b study in cystic fibrosis (CF), with results anticipated in H1 2026. BiomX received $36.8 million in non-dilutive funding from the US Defense Health Agency to support the DFO program. The company remains optimistic about its phage therapy programs, which target specific pathogenic bacteria, and their potential to address unmet medical needs.
Investment
growth-positive
BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024
BiomX Inc., a clinical-stage company specializing in phage therapies, announced it will host a conference call and webcast on November 14, 2024, to discuss its third-quarter financial results and provide updates on its business and programs. The company focuses on developing phage cocktails and personalized treatments targeting harmful bacteria to address chronic diseases with unmet needs. BiomX utilizes its BOLT platform to customize phage compositions for specific bacterial targets. The webcast will be accessible on the companys website.
growth-negative
BiomX announces mandatory unit separation
BiomX has announced a mandatory separation of its trading units, which are currently listed under the ticker symbol PHGE.U. Each unit comprises one share of Common Stock and one warrant to purchase half a share of Common Stock. The separation will occur on or about October 25, 2024, after which the units will no longer trade on the NYSE American. Unit holders will automatically receive the shares and warrants underlying their units, with no action required on their part. The warrants will expire on October 28, 2024. Following the separation, the shares of Common Stock will trade under the symbol PHGE. This move is part of BiomXs broader strategy, which includes advancing phage therapy and presenting clinical trial data.
Public Trading
growth-negative
BiomX Announces a Mandatory Unit Separation
BiomX Inc., a clinical-stage company specializing in phage therapies, announced a mandatory separation of its trading units on October 15, 2024. The units, which consist of one share of Common Stock and a warrant to purchase half a share, will be separated on or about October 25, 2024. Post-separation, the shares will trade under the symbol PHGE, while the warrants will expire on October 28, 2024. This separation is automatic, requiring no action from unit holders. BiomX focuses on developing phage treatments targeting harmful bacteria for chronic diseases. The separation could impact the companys stock trading dynamics negatively.
growth-positive
BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference
BiomX Inc., a clinical-stage company, announced the presentation of further data from its Phase 1b/2a study of BX004 for treating cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infections. The findings will be shared at the North American Cystic Fibrosis Conference in Boston. The study showed promising results, with subjects receiving BX004-A showing significant reductions in P. aeruginosa colony-forming units and improved lung function compared to placebo. BiomX plans to initiate a Phase 2b trial in CF patients, with results expected in Q3 2025. The FDA has granted BX004 Fast Track and Orphan Drug Designations.
Customers
growth-positive
BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference
BiomX Inc., a clinical-stage company specializing in phage therapies, announced that its CEO, Jonathan Solomon, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, at the Lotte New York Palace Hotel. The presentation will be available on BiomXs website for 90 days. The company focuses on developing phage cocktails and personalized treatments targeting harmful bacteria to address chronic diseases. The conference provides an opportunity for BiomX to engage with potential investors and partners.
Investment
growth-positive
BiomX to Present Positive Phase 1b/2a Clinical Trial Data for BX004 at the European Respiratory Society (ERS) Congress 2024
BiomX Inc., a clinical-stage company, announced positive results from its Phase 1b/2a study of BX004 for treating cystic fibrosis patients with chronic Pseudomonas aeruginosa infections. The data will be presented at the European Respiratory Society Congress in Vienna. The study showed that BX004-A demonstrated favorable safety and notable efficacy, including improved lung function and reduced bacterial burden. The company plans to initiate a Phase 2b trial in the third quarter of 2025. The FDA has granted BX004 Fast Track and Orphan Drug Designations.
Customers
growth-negative
UPDATE ON UNITS - BiomX Inc. Announces 1-for-10 Reverse Stock Split
BiomX, a clinical-stage company developing novel natural and engineered phage therapies, has announced plans to effect a one-for-ten reverse stock split of the company’s common stock. The stock will continue to trade on the NYSE American under the existing symbol “PHGE” and will begin trading on a split-adjusted basis on August 26, 2024. The reverse stock split will affect all stockholders uniformly and will not alter any stockholder’s percentage ownership interest in the company’s equity. The number of outstanding shares of common stock will be reduced from approximately 178,958,447 to approximately 17,895,845.
Public Trading
growth-negative
BiomX Inc. Announces 1-for-10 Reverse Stock Split
BiomX Inc., a clinical-stage company developing phage therapies, announced its plans to implement a one-for-ten reverse stock split of the company’s common stock. The stock will continue to trade on the NYSE American under the existing symbol “PHGE”. The reverse stock split was previously approved by the company’s stockholders at a special meeting held on July 9, 2024. The reverse stock split will affect all stockholders uniformly and will not alter any stockholder’s percentage ownership interest in the company’s equity. The number of outstanding shares of common stock will be reduced from approximately 178,958,447 to approximately 17,895,845.
Public TradingManagement Changes
growth-positive
BiomX Reports Second Quarter 2024 Financial Results and Provides Business and Program Updates
BiomX Inc., a clinical-stage company advancing novel natural and engineered phage therapies, has announced its financial results for the second quarter ended June 30, 2024. The company has made significant progress in its programs and continues to integrate its leading phage therapy pipeline following its merger with Adaptive Phage Therapeutics. The companys stockholders have approved the conversion of preferred stock to common stock. BiomX is focusing on advancing its clinical-stage candidates — BX004 and BX211 — toward reporting of key Phase 2 findings in 2025.
InvestmentAcquisitionPublic Trading
Neutral
BiomX to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 15, 2024
BiomX Inc., a clinical-stage company developing novel natural and engineered phage therapies, announced that it will host a conference call and a live audio webcast on August 15, 2024, to report its second quarter 2024 financial results and provide business and program updates. The company is leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases.
Customers
Growth-Positive
BiomX Inc. Announces NYSE American Acceptance of Plan to Regain Listing Compliance
BiomX Inc., a clinical-stage company developing novel natural and engineered phage therapies, has received acceptance from the NYSE American for its plan to regain compliance with the NYSE Americans listing standards. The company has been granted until November 23, 2025, to regain compliance. If BiomX does not regain compliance by this date or does not make sufficient progress, the NYSE American may initiate delisting proceedings. The acceptance has no immediate impact on the listing of the companys shares, which will continue to be listed and traded on the NYSE American during the Plan Period.
Public Trading
growth-positive
BiomX Inc. Announces Stockholder Approval for Conversion of Outstanding Series X Convertible Preferred Stock to Common Stock
BiomX Inc., a clinical-stage company, has announced that its stockholders have voted to approve a proposal to convert BiomX’s outstanding Series X Non-Voting Convertible Preferred Stock into shares of BiomX’s common stock. This follows BiomXs acquisition of Adaptive Phage Therapeutics, Inc. (APT) and a concurrent $50 million financing in March 2024. The conversion will result in up to 256,887,000 shares of the Company’s common stock being added to the Company’s outstanding share count. The company expects to regain compliance with the NYSE American’s listing requirements as a result.
AcquisitionInvestment
growth-negative
BiomX Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
BiomX Inc., a clinical-stage company, has received a notice from the NYSE American stating that it is no longer in compliance with continued listing standards due to reported losses and a total stockholders’ capital deficiency of $9,544,000 as of March 31, 2024. The company has until June 22, 2024, to submit a plan of compliance to regain compliance by November 23, 2025. BiomX had previously acquired Adaptive Phage Therapeutics and made a private investment in public equity resulting in gross proceeds of approximately $50 million. The company is expected to ask its stockholders to approve the conversion of the Company’s Series X Non-Voting Convertible Preferred Stock into Common Stock in July 2024.
Public TradingAcquisitionInvestment
growth-positive
BiomX to Present Phase 1b/2a Clinical Trial Data for BX004 at the 47th European Cystic Fibrosis Conference and at ASM Microbe 2024
BiomX Inc., a clinical-stage company developing phage therapies, announced it will present data from its Phase 1b/2a study of BX004 for the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infections at two upcoming conferences. The findings will be presented at the 47th European Cystic Fibrosis Conference and the American Society for Microbiology Microbe 2024 meeting. BiomX announced positive topline results from Part 2 of the Phase 1b/2a trial where BX004 demonstrated improvement in pulmonary function associated with a reduction in P. aeruginosa burden compared to placebo in a predefined subgroup of patients with reduced lung function.
CustomersExpand
growth-positive
BiomX Reports First Quarter 2024 Financial Results and Provides Business and Program Updates
BiomX Inc., a clinical-stage company developing novel natural and engineered phage therapies, has reported its financial results for Q1 2024, following its merger with Adaptive Phage Therapeutics (APT) in March 2024 and a concurrent $50 million private placement. The company has a cash balance of $44.1 million and estimates a cash runway through Q4 2025. BiomX is advancing two lead programs, BX211 and BX004, with Phase 2 readouts expected in 2025. The company raised $50 million in a private placement led by top institutional healthcare investors, including affiliates of Deerfield Management and the AMR Action Fund, and additional investors including the Cystic Fibrosis Foundation, OrbiMed, and Nantahala Capital Management.
Acquired-byInvestment
Neutral
BiomX to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 21, 2024
BiomX Inc., a clinical-stage company developing novel natural and engineered phage therapies, has announced it will host a conference call and live audio webcast on May 21, 2024, to report its first quarter 2024 financial results and provide business and program updates. The company is leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases.
growth-positive
BiomX to Present at the 2024 RBC Capital Markets Global Healthcare Conference
BiomX Inc., a clinical-stage company developing novel natural and engineered phage therapies, announced its participation in the RBC Capital Markets Global Healthcare Conference in New York City on May 15, 2024. The companys Chief Business Officer, Assaf Oron, will be presenting and participating in one-on-one meetings. The live webcast of the presentation will be available on the companys website and will be archived for a period of 3 months.
Expand
growth-positive
BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)
BiomX Inc., a clinical-stage company developing phage therapies, has announced it will present data from the Phase 1b/2a study of BX004 for the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infections at ECCMID 2024. The abstract submitted by the Company was selected as a “Top Poster”, ranking it among the 1-2% of top-rated abstracts. The company expects to initiate a randomized, double blind, placebo-controlled, multi-center Phase 2b trial in CF patients with chronic P. aeruginosa pulmonary infections in the fourth quarter of 2024. The trial is designed to demonstrate microbiologic reduction of P. aeruginosa burden in sputum and evaluate clinical parameters such as lung function measured by FEV1 and patient reported outcomes.
Customers
growth-positive
BiomX Announces the Appointment of Susan Blum to its Board of Directors
BiomX Inc., a clinical-stage company developing novel natural and engineered phage therapies, has announced the appointment of Susan Blum to its Board of Directors. Blum, who is the CFO of Melinta Therapeutics, will also serve as a member and chair of the audit committee of the Board. The appointment comes at a significant time for BiomX, which is in the process of integrating the recently acquired Adaptive Phage Therapeutics and advancing its two clinical-stage programs, BX004 and BX211.
Management Changes
growth-negative
Here's Why BiomX (PHGE) Is a Great 'Buy the Bottom' Stock Now
The stock price of BiomX Inc. has been on a downward trend, losing 15.6% over the past week. However, the formation of a hammer chart pattern in its last trading session indicates a potential trend reversal. This pattern, along with Wall Street analysts raising earnings estimates for the company, suggests a bullish case for the stock. The consensus EPS estimate for the current year has increased 38% over the last 30 days. BiomX currently has a Zacks Rank #2 (Buy), indicating it is in the top 20% of more than 4,000 stocks ranked based on trends in earnings estimate revisions and EPS surprises.
Investment
growth-negative
BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure
BiomX Inc., a clinical-stage company developing phage therapies, has announced that its audit opinion contained a going concern qualification. This announcement was made to comply with the NYSE American Company Guide Sections 401(h) and 610(b), which require separate disclosure of receipt of an audit opinion that contains a going concern qualification. The announcement does not represent any change or amendment to the companys 2023 audited financial statements or to its 2023 annual report on Form 10-K.
Public Trading
growth-positive
BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
BiomX Inc., a clinical-stage company developing phage therapies, has reported its financial results for Q4 and full year 2023. The company highlighted its acquisition of Adaptive Phage Therapeutics and a concurrent $50 million financing to support its BX004 and BX211 programs. The acquisition has positioned BiomX as a leader in phage therapy with an advanced clinical-stage pipeline. The company also reported progress in patient recruitment for its BX211 Phase 2 trial in Diabetic Foot Osteomyelitis, with top-line results expected in Q1 2025.
AcquisitionInvestment
Neutral
BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024
BiomX Inc., a clinical-stage company developing novel natural and engineered phage therapies, has announced it will host a conference call and live audio webcast on April 3, 2024, to report its fourth quarter and full year 2023 financial results and provide a business update. The live and archived webcast will be available in the Investors section of the companys website. No specific details about the financial results or business updates were provided in the announcement.
growth-positive
BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing
BiomX Inc. has announced the completion of its acquisition of Adaptive Phage Therapeutics, Inc. (APT), a clinical-stage biotechnology company. The acquisition will allow BiomX to advance its phage therapy pipeline, which includes two Phase 2 assets for the treatment of chronic pulmonary infections in cystic fibrosis patients and diabetic foot osteomyelitis. The company has also announced a $50 million private placement led by Deerfield Management Company and the AMR Action Fund, with additional investors including the Cystic Fibrosis Foundation, OrbiMed, and Nantahala Capital. The funds will be used to advance the two lead product candidates through Phase 2 clinical readouts in 2025.
AcquisitionInvestment
growth-positive
Phage therapy co BiomX merges with APT, raises $50m
Israeli phage therapy company BiomX has announced a merger with Adaptive Phage Therapeutics (APT) and is raising $50 million in a private placement. Existing shareholders in BiomX will hold 55% of the merged company. Following the announcement, BiomXs share price rose 150% on Wall Street. BiomX has been trading on the NYSE since 2019, when it became one of the first Israeli companies to complete a SPAC merger. The companys lead product is designed to treat bacterial infections in patients with genetic lung disease cystic fibrosis. BiomXs management headed by CEO Jonathan Solomon will continue to lead the merged company.
Acquired-byInvestmentManagement Changes
growth-positive
BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing
BiomX, a clinical-stage company developing phage therapies, has announced a merger with Adaptive Phage Therapeutics (APT), a biotechnology company pioneering the development of phage-based therapies. Concurrently, BiomX has secured $50 million in private placement financing, led by Deerfield Management Company and the AMR Action Fund, among others. The funds will be used to advance two lead product candidates through Phase 2 clinical readouts in 2025. The merger is expected to close within the next 30 days, subject to the satisfaction of the closing conditions. Post-merger, the former stockholders of BiomX will own approximately 55% and the former stockholders of APT will own approximately 45% of the consolidated entity.
AcquisitionInvestmentManagement Changes
growth-positive
BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fibrosis
BiomX Inc., a clinical-stage company, has announced that its phage cocktail, BX004, has been granted Orphan Drug Designation (ODD) by the United States Food and Drug Administration (FDA) for the treatment of chronic pulmonary infection caused by Pseudomonas aeruginosa in patients with cystic fibrosis. The FDA had previously granted BX004 Fast Track designation in August 2023. The company believes BX004 holds significant potential to improve upon the current standard of care and plans to further advance the clinical development of BX004.
Investment
growth-positive
BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023
BiomX Inc., a clinical-stage company advancing novel natural and engineered phage therapies, announced it will host a virtual KOL Event on December 4, 2023, to discuss the positive topline results from Part 2 of Phase 1b/2a trial of BX004 in cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa infections. The event will feature Dr. Eitan Kerem, M.D. (Hadassah University Medical Center) and Dr. Robert T. “Chip” Schooley, M.D. (University of California, San Diego), who will discuss phage therapy, the current treatment landscape, and the unmet medical need in cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa respiratory infections.
InvestmentExpand
growth-positive
BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis
BiomX Inc. has announced positive safety and efficacy results from Part 2 of the Phase 1b/2a trial evaluating the companys novel phage cocktail, BX004, for the treatment of chronic pulmonary infections caused by Pseudomonas aeruginosa in patients with cystic fibrosis. The company plans to advance the BX004 program to a larger, pivotal Phase 2b/3 trial, subject to regulatory feedback and availability of sufficient funding. The results showed clinically meaningful improvement in pulmonary function and a reduction in P. aeruginosa bacterial burden. The study drug was safe and well-tolerated, with no related serious adverse events or related acute pulmonary exacerbations.
InvestmentExpand
growth-positive
BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update
BiomX Inc., a clinical-stage company developing novel natural and engineered phage therapies, has reported its financial results for Q3 2023 and provided a business update. The company is currently analyzing data from Part 2 of the Phase 1b/2a trial of BX004 and expects to announce the results later this month. BX004 received FDA Fast Track designation in August. The company also announced the appointment of Edward L. Williams to its Board of Directors. As of September 30, 2023, the company had a cash balance of $23.4 million, compared to $34.3 million as of December 31, 2022.
Management ChangesInvestment
growth-positive
BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the 37th Annual North American Cystic Fibrosis Conference
BiomX Inc., a clinical-stage company developing phage therapies, announced that it will present data from Part 1 of its ongoing Phase 1b/2a study of BX004, a novel phage product candidate for the treatment of chronic Pseudomonas aeruginosa pulmonary infections in cystic fibrosis patients, at the 37th Annual North American Cystic Fibrosis Conference. The Phase 1b/2a data for BX004 will also be available as an e-poster on the virtual congress platform. The Phase 1b/2a trial is composed of two parts, with results from Part 2 of the trial expected in November 2023.
InvestmentExpand
BiomX Announces the Appointment of Edward L. Williams to its Board of Directors
growth-positive
BiomX Announces Completion of Patient Dosing in Part 2 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis
BiomX Inc., a clinical-stage company developing novel natural and engineered phage therapies, has completed patient dosing in Part 2 of the Phase 1b/2a trial evaluating the Company’s novel phage cocktail, BX004, for the treatment of chronic pulmonary infections caused by Pseudomonas aeruginosa in patients with cystic fibrosis. The company is on track to report results from Part 2 of the study in November 2023. The Part 1 data has been accepted for oral presentation at the upcoming IDWeek 2023 meeting.
Investment
growth-positive
BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the European Respiratory Society (ERS) International Congress 2023
BiomX Inc., a clinical-stage company, announced that it will present data from Part 1 of its ongoing Phase 1b/2a study evaluating the novel phage product candidate, BX004, for the treatment of chronic Pseudomonas aeruginosa pulmonary infections in patients with cystic fibrosis at the European Respiratory Society International Congress 2023. The Phase 1b/2a data for BX004 will also be available as an e-poster on the virtual congress platform. BX004 is being developed for the treatment of chronic respiratory infections caused by P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.
Investment
Growth-Positive
BiomX to Present at H.C. Wainwright 25th Annual Global Investment Conference
BiomX Inc., a clinical-stage company developing novel natural and engineered phage therapies, announced that its CEO, Jonathan Solomon, will be presenting at the H.C. Wainwright 25th Annual Global Investment Conference, which is being held virtually and in person on September 11-13, 2023, at Lotte New York Palace Hotel in New York City. The presentation will be available on-demand and a webcast of the presentation will also be accessible through the Investors section of the Company’s website.
Investment
growth-positive
BiomX Reports Second Quarter 2023 Financial Results and Provides Business Update
BiomX Inc., a clinical-stage company developing phage therapies, has completed patient screening for Part 2 of its Phase 1b/2a trial of BX004, a treatment for cystic fibrosis. The company expects patient enrollment to exceed original estimates and has received Fast Track designation from the FDA. Initial data from Part 2 is expected in November 2023. BiomX also announced the appointments of Jason M. Marks and Michael E. Dambach to its Board of Directors and the second closing of its $7.5 million private placement investment. The company reported a net loss of $6.4 million for Q2 2023.
CustomersInvestmentManagement Changes
Growth-Positive
BiomX to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 9th, 2023
BiomX Inc., a clinical-stage company developing novel natural and engineered phage therapies, has announced that it will host a conference call and a live audio webcast on August 9th, 2023, to report its second quarter 2023 financial results and provide business updates. The company is known for its development of phage cocktails designed to target and destroy bacteria in the treatment of chronic diseases.
CustomersInvestment
growth-negative
NYSE American Initiates Delisting Proceedings for BiomX Warrants
BiomX Inc. announced that its warrants are in the process of being delisted from NYSE American. The delisting is expected to have no impact on the trading of the companys common stock and units. The delisting proceedings were initiated due to the low trading price of the warrants. BiomX is a clinical-stage company developing phage therapies for the treatment of chronic diseases.
Public Trading
growth-positive
BiomX to Present Part 1 Data from Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis During Late-Breaking Science Session at the 46th European Cystic Fibrosis Conference (ECFC)
BiomX Inc. will present Part 1 data from its ongoing Phase 1b/2a study evaluating the novel phage product candidate, BX004, for the treatment of chronic Pseudomonas aeruginosa (PsA) pulmonary infections in patients with cystic fibrosis (CF) at the 46th European Cystic Fibrosis Conference. The Phase 1b/2a data will also be presented as a poster at the conference. BiomX is developing BX004 for the treatment of CF patients with chronic pulmonary infections caused by P. aeruginosa. Part 2 of the Phase 1b/2a study will evaluate the safety and efficacy of BX004 in 24 CF patients with chronic pulmonary infection caused by P. aeruginosa. Results from Part 2 are expected in the third quarter of 2023.
Customers
growth-positive
BiomX Announces the Appointments of Jason M. Marks and Michael E. Dambach to Board of Directors | MarketScreener
BiomX Inc. has announced the appointments of Jason M. Marks and Michael E. Dambach to its Board of Directors. The company expects their experience and expertise in the life sciences sector to guide their financial, legal, governance, and regulatory decisions as they advance their lead program, BX004, in cystic fibrosis. Jason M. Marks is a senior global life sciences executive with extensive experience in public company board management, while Michael E. Dambach has over two decades of experience in the life sciences and financial services sectors. BiomX is a clinical-stage company developing phage therapies to target and destroy specific pathogenic bacteria in the treatment of chronic diseases.
Management Changes
growth-positive
BiomX Reports First Quarter 2023 Financial Results and Provides Business Update
BiomX Inc. has announced positive results from Part 1 of its ongoing Phase 1b/2a trial of BX004 for the treatment of lung infections in cystic fibrosis patients. The company also completed the second and final closing of a PIPE investment, raising a total of $7.5 million. This funding is expected to last until the third quarter of 2024. Additionally, Jason M. Marks and Michael E. Dambach have been appointed to the companys board of directors. BiomX is also collaborating with Maruho Co. Ltd. on a range of pre-clinical activities.
InvestmentManagement Changes
BiomX Announces the Appointments of Jason M. Marks and Michael E. Dambach to Board of Directors
Neutral
BiomX to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 15th, 2023
BiomX Inc., a clinical-stage company developing novel natural and engineered phage therapies, announced that it will host a conference call and a live audio webcast on May 15, 2023, to report its first quarter 2023 financial results and provide business updates. The call will be available for participation via dial-in numbers and the live and archived webcast will be accessible in the Investors section of the companys website.
growth-positive
BiomX Announces Second Closing of $7.5 Million Private Placement
BiomX Inc. has announced the second closing of its $7.5 million private placement investment. The financing was structured to close in two separate parts, with the first closing occurring on February 27, 2023. The second closing, announced on May 5, 2023, was contingent upon approval of the issuance of additional securities under the securities purchase agreement by the companys stockholders. The company issued 24,632,243 shares of common stock for gross proceeds of approximately $6 million. The net proceeds, along with existing cash and cash equivalents, will be used to fund clinical development, research activities, and other general corporate purposes. The securities sold in the private placement have not been registered and may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption.
Investment
BiomX Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
BiomX to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on March 29th, 2023
growth-positive
BiomX reports "impressive" data in first bacteriophage trial
BiomX conducted a study on the use of bacteriophages as a therapeutic strategy for resistant bacterial infections in cystic fibrosis patients. The results showed a significant reduction in bacterial burden in patients with chronic infections. The phase 1 portion of the study demonstrated efficacy, safety, and tolerability of the BX004 bacteriophage cocktail. BiomX has received positive feedback from analysts and is proceeding with the phase 2 portion of the study. The company also announced a $7.5 million private placement backed by existing investors Orbimed and the Cystic Fibrosis Foundation to fund further clinical development.
CustomersInvestment
BiomX Announces Positive Results from Part 1 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis
growth-positive
BiomX Announces $7.5 Million Private Placement
BiomX Inc., a clinical-stage company developing phage therapies, has entered into a securities purchase agreement with a group of investors, including OrbiMed and the Cystic Fibrosis Foundation. The company plans to issue and sell over 30 million shares of its common stock at $0.245 per share, expecting to raise approximately $7.5 million. The funds will be used to fund clinical development of BX004 for the treatment of lung infections in patients with cystic fibrosis, among other purposes. The financing is expected to close in two parts, with the first closing anticipated to occur promptly and the second in the second quarter of 2023.
Investment
growth-positive
BiomX Announces $7.5 Million Private Placement
BiomX Inc., a clinical-stage company, has announced a securities purchase agreement with a group of investors, including OrbiMed and the Cystic Fibrosis Foundation. The company will issue and sell over 30 million shares of its common stock at $0.245 per share, expecting to raise approximately $7.5 million. The funds will be used to fund clinical development of BX004 for the treatment of lung infections in patients with cystic fibrosis, the development of other programs, research activities, working capital, and other general corporate purposes.
Investment
BiomX To Present at H.C. Wainwright 1st Annual Investor Conference on Bacteriophage
growth-positive
BiomX Reports Third Quarter 2022 Financial Results and Provides Business Update
BiomX Inc., a clinical-stage microbiome company, has reported its financial results for Q3 2022 and provided a business update. The company is making progress in enrolling patients for its Phase 1/2 trial of BX004 for the treatment of lung infections in cystic fibrosis patients. Results from Part 1 of the trial are now expected in Q1 2023. BiomX has also announced the publication of research in Cell demonstrating the proof-of-concept assessment of orally administered phage treatment in a preclinical model of inflammatory bowel disease. The companys cash runway is expected to last until mid-2024.
InvestmentPartners
BiomX to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022
BiomX To Present at H.C. Wainwright 24th Annual Global Investment Conference
growth-positive
BiomX Reports Second Quarter 2022 Financial Results and Provides Business Update
BiomX Inc., a clinical-stage microbiome company, has reported its financial results and provided a business update for Q2 2022. The company has continued enrollment in the Phase 1/2 trial of BX004 for the treatment of lung infections in cystic fibrosis patients, with results expected by Q3 2022. BiomX has also entered into a second collaboration with Boehringer Ingelheim to discover microbiome markers for inflammatory bowel disease. The company has also announced publications in the Journals Cell and Bioinformatics. BiomX has a cash runway through multiple data readouts and extended to at least mid-2024.
PartnersInvestmentManagement Changes
Growth-Positive
BiomX to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 10, 2022
BiomX Inc., a clinical-stage microbiome company, has announced that it will host a conference call and live audio webcast on August 10, 2022, to report its second quarter 2022 financial results and provide business updates. The company is known for advancing novel natural and engineered phage therapies that target specific pathogenic bacteria. The live and archived webcast will be available in the Investors section of the companys website.
Investment
BiomX Announces Publication in Cell of Research Demonstrating Proof-of-Concept Assessment of Orally Administered Phage Treatment in Preclinical Model of Inflammatory Bowel Disease
BiomX Announces Publication in Cell of Research Demonstrating Proof-of-Concept Assessment of Orally Administered Phage Treatment in Preclinical Model of Inflammatory Bowel Disease
BiomX Announces Voluntary Delisting from the Tel Aviv Stock Exchange
Boehringer Ingelheim and BiomX Collaborate to Discover Inflammatory Bowel Disease Microbiome Biomarkers
Boehringer Ingelheim and BiomX Collaborate to Discover Inflammatory Bowel Disease Microbiome Biomarkers
BiomX Announces Dosing of the First Two Patients in Phase 1b/2a Study of BX004 for Treatment of Chronic Respiratory Infections in Patients with Cystic Fibrosis
BiomX Announces Dosing of the First Two Patients in Phase 1b/2a Study of BX004 for Treatment of Chronic Respiratory Infections in Patients with Cystic Fibrosis
growth-negative
"החלטה שעושה כאב בטן": חברת ביומיקס פיטרה 50% מעובדיה
BiomX, a company developing virus-based drugs to combat bacteria, has laid off 50% of its employees as part of a restructuring plan due to market conditions. The company employed around 110 workers. The cost-cutting measures aim to extend the companys operational time with the available funds until at least mid-2024. As part of the restructuring, BiomX will delay its plans in the field of atopic dermatitis treatment.
Layoffs
BiomX Announces Corporate Restructuring
BiomX Announces Therapeutics Development Award of up to $5 Million from the Cystic Fibrosis Foundation
growth-positive
BiomX Announces Agreement with Maruho Co., Ltd. for Atopic Dermatitis Product Candidate BX005
BiomX Inc., a clinical-stage microbiome company, has entered into an agreement with Maruho Co. Ltd., a leading dermatology-focused pharmaceutical company in Japan. The agreement grants Maruho a right of first offer to license BiomX’s atopic dermatitis product candidate, BX005, in Japan. The right of first offer will commence following the availability of results from the Phase 1/2 study of BX005 expected in 2022. Maruho also entered into a binding agreement for an equity investment in BiomX of $3 million at a premium to the market share price, intended primarily to support the Phase 1/2 study.
InvestmentPartners
growth-positive
BiomX Inc. Announces $15 Million Registered Direct Offering
BiomX Inc., a clinical-stage microbiome company, has announced a definitive agreement with institutional investors, directors, and certain executive officers for the purchase and sale of an aggregate of 3,750,000 shares of the company’s common stock and warrants. The registered direct offering is expected to generate gross proceeds of $15 million. The funds will be used to support clinical trials and for general corporate purposes. The closing of the offering is expected to occur on or about July 28, 2021.
Investment
growth-positive
BiomX Announces Dosing of First Subject in Phase 2 Study of BX001 for Acne-Prone Skin
BiomX Inc., a clinical-stage company, has announced the initiation of a Phase 2 cosmetic clinical study of BX001 in subjects with mild-to-moderate acne. BX001 is a topical gel comprised of a cocktail of naturally-occurring phage targeting Cutibacterium acnes, bacteria implicated in the pathophysiology of acne vulgaris. The study aims to provide clinically meaningful improvement of the appearance of acne-prone skin. The trial will evaluate a larger number of subjects with acne-prone skin over 8 to 12 weeks. Results from the 8-week time point are expected to be available in the third quarter of 2021.
InvestmentExpand
BiomX Announces Positive Results of a Phase 1a Pharmacokinetic Study for Inflammatory Bowel Disease/Primary Sclerosing Cholangitis (IBD/PSC) Evaluating Delivery of Oral BX002 Phage Therapy
N/A
BiomX Announces Presentation Of Preclinical Results Of Analysis Of Patient Samples And Engineering Of Phage For Therapeutic Applications In Colorectal Cancer - Benzinga
The article is a sample of real-time intelligence provided by Benzinga Pro for traders in the stock market.
BiomX Announces Dosing of First Subject in Phase 1a Study of BX002 Phage Therapy for Inflammatory Bowel Disease
BiomX Appoints Paul Sekhri and Alan Moses, M.D., to Board of Directors
growth-positive
BiomX Enters Collaboration with Boehringer Ingelheim with the Goal of Discovering Microbiome-Based Biomarkers for Inflammatory Bowel Disease
BiomX Inc., a clinical stage company developing phage therapies, has announced a collaboration with Boehringer Ingelheim to use the BiomX XMarker microbiome-based biomarker discovery platform to potentially identify biomarkers associated with patient phenotypes in inflammatory bowel disease (IBD). The collaboration will generate metagenomic data of gut microbiome samples obtained from IBD patients with the aim of identifying biomarkers using the XMarker platform. The terms of the collaboration also include an option for Boehringer Ingelheim to negotiate an exclusive right to biomarkers discovered utilizing the XMarker platform.
Partners
BiomX Discloses Acne Pre-clinical Data Planned for 2020 AAD Annual Meeting
BiomX Announces Dual Listing on the Tel-Aviv Stock Exchange
BiomX Presents Preclinical Results of its Phage Therapy Program Targeting Primary Sclerosing Cholangitis
BiomX To Present at Plenary Session of the AASLD Liver Conference
BiomX Appoints Russell G. Greig, Ph.D, as Chairman of the Board of Directors and Lynne Sullivan as Board Director
growth-positive
Chardan Healthcare Acquisition Corp. Completes Merger with BiomX Ltd.
Chardan Healthcare Acquisition Corp. has announced the completion of its merger with BiomX Ltd., a microbiome company developing phage therapies. The combined company has been renamed BiomX Inc. and will begin trading on the NYSE American stock exchange. BiomXs current management team will continue to lead the company. The merger provides BiomX with growth capital to support its pipeline of phage-based products for various chronic diseases. Existing shareholders and new investors, including OrbiMed and Johnson & Johnson Innovation, participated in the financing. BiomXs CEO expressed excitement about the potential of phage therapies to treat multiple chronic diseases.
Acquisition
growth-positive
BiomX Appoints Merav Bassan as Chief Development Officer
BiomX Ltd., a microbiome company developing phage therapies, has announced the appointment of Merav Bassan, Ph.D., as Chief Development Officer (CDO). Dr. Bassan will oversee BiomXs pre-clinical and clinical development as the company advances its phage therapies into the clinic. Dr. Bassan has over 20 years of leadership experience with clinical and drug development teams in her various roles at Teva Pharmaceutical and other smaller biotech companies.
Management Changes
growth-positive
BiomX Presents In Vivo Data on Bacteriophage Delivery to Intra-Tumor Bacteria
BiomX Ltd., a microbiome company, has presented new data from its colorectal cancer synthetic biology program at the Fifth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference in Paris, France. The program targets bacteria present in tumors, aiming to convert cold tumors to hot by releasing an immunostimulatory payload and eradicating tumor-protective bacteria. The companys researchers have isolated phage that specifically target Fusobacterium nucleatum, a bacterial species enriched in colorectal cancer tumors. The results represent a first step in BiomXs strategy to alter the tumor microenvironment.
Customers
growth-positive
BiomX Announces In-house Phage Manufacturing Facility
BiomX Ltd., a microbiome company, has announced the completion of a new manufacturing facility at its headquarters in Ness Ziona, Israel. The facility will support the clinical manufacturing of BiomXs candidate phage products and could be expanded to support commercial manufacturing needs in the future. The companys CEO, Jonathan Solomon, stated that owning and operating their own manufacturing facility provides them with a competitive advantage. The new facility will support the manufacturing of BX002, a drug candidate phage cocktail designed to target bacterial strains that potentially have a role in the onset and aggravation of inflammatory bowel disease (IBD).
Expand
BiomX to raise $70m in NYSE reverse merger with Chardan
growth-positive
BiomX Licenses Novel Targets for Liver Disease Phage Therapy Program From JSR Corporation in Japan
BiomX Ltd., a microbiome company, has licensed a new set of bacterial targets from JSR Corporation for the development of phage therapies for Primary Sclerosing Cholangitis (PSC), a rare liver disease. The targets were discovered by a research team at Keio University School of Medicine. BiomX is using its advanced discovery and development capabilities in phage therapy to develop a therapeutic for PSC. This is the second collaboration between BiomX and JSR Corporation.
Partners
growth-positive
Israeli microbiome co BiomX raises $32m
Israeli microbiome company BiomX Ltd. has raised $32 million in a series B financing round. The funds will be used to advance the company’s leading drug candidates for the treatment of acne and Inflammatory Bowel Disease (IBD) to the clinical stage. The round was led by existing investors OrbiMed, Johnson & Johnson Innovation - JJDC, Inc., Takeda Ventures, Inc., 8VC, MiraeAsset, Seventure Partners’ Health for Life Capital I, SBI Japan-Israel Innovation Fund and additional European investors. The round also included new investors led by RM Global Partners (RMGP) BioPharma Investment Fund, with participation from Chong Kun Dang Pharmaceutical Corp., Handok, Inc., KB Investment Co., Ltd. and Consensus Business Group.
InvestmentExpand
growth-positive
Israeli microbiome co BiomX teams with J&J
Israeli microbiome company BiomX has entered into a partnership with Janssen, the therapy R&D arm of Johnson & Johnson. The collaboration will utilise BiomXs XMarker microbiome-based biomarker discovery platform to stratify responders and non-responders to inflammatory bowel disease (IBD) therapeutics. BiomXs XMarker platform applies a metagenomics-based approach to decipher full microbial genomic signatures that can be further developed into predictive biomarkers. BiomX, which has 60 employees, was founded in the FutuRX biotechnology incubator, based on research by professors from the Weizmann Institute of Science and MIT.
PartnersInvestment
growth-positive
BiomX Appoints Sailaja Puttagunta as Chief Medical Officer
BiomX Ltd., a microbiome company developing customized phage therapies, has appointed Dr. Sailaja Puttagunta as its Chief Medical Officer. Dr. Puttagunta will oversee BiomXs clinical development and strategy as the company prepares to enter the clinic with its Acne and Irritable Bowel Disease programs. The companys Acne program is expected to enter the clinic in mid 2019, and the IBD program is expected to commence clinical trials in 2020. Dr. Puttagunta will be based in United States East Coast and will work closely with BiomXs Israeli management.
Management Changes
growth-positive
BiomX Licenses Novel Bacterial Targets for the Treatment of Inflammatory Bowel Disease
BiomX Ltd., a microbiome company, has exclusively sub-licensed a set of bacterial targets from JSR Corporation for the development of phage therapies to treat inflammatory bowel disease (IBD). The targets were discovered by Dr. Kenya Honda at Keio University School of Medicine and have been shown to be pro-inflammatory, potentially playing a role in the onset and aggravation of IBD. BiomX is developing BX002, a phage composition designed to target and eradicate these IBD-associated bacteria, and plans to file an investigational new drug application with the FDA in 2019.
Partners
growth-positive
BiomX Acquires RondinX to Boost Microbiome Discovery and Development Capabilities
BiomX Ltd. has announced the acquisition of RondinX, which strengthens its bacterial target discovery capabilities and expands its therapeutic pipeline. The financial terms of the acquisition were not disclosed. In addition, 8VC, an angel investor in RondinX, made an undisclosed equity investment in BiomX. The RondinX technology is based on research from the Weizmann Institute of Science. BiomX is a microbiome drug discovery company developing customized phage therapies for chronic diseases. The companys investors include OrbiMed Israel Incubator LP, Johnson & Johnson Development Corporation Inc., Takeda Ventures, Inc., Seventure Partners Health for Life Capital fund, Mirae Asset Global Investments, and SBI.
Acquisition
Israeli startup seeks to replace antibiotics
Microbiome therapeutics co BiomX raises $24m
BiomX Team
Employee Info
| Employees (range) | 51-200 |
| Exact count | 62 |
| Team members | 7 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 12 classification IDs that could be used for matching.
BiomX Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 99/100 |
| Missing | video or image, markets |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 515220556 |
| Crunchbase | biomx-inc |
| Phone | +972723942377 |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-04-30T00:00:00.000Z |
| Created | 2016-03-10T00:00:00.000Z |
| Claimed | Yes |
| Status detail | Public on NYSE on Nov, 2019; |